Skip to main content

Romina Dieli Crimi

Sóc metgessa immunòloga i durant la meva carrera professional em vaig especialitzar en el diagnòstic i tractament de patologies immunomediades, entre les quals es troben les immunodeficiències primàries i secundàries. També realitzo treball de laboratori contribuint al diagnòstic de les diferents patologies relacionades amb el sistema del complement.

Institutions of which they are part

Translational Immunology
Vall Hebron Institut de Recerca
Doctor
Immunology
Cross-departmental services
Romina Dieli Crimi

Romina Dieli Crimi

Romina Dieli Crimi

Institutions of which they are part

Translational Immunology
Vall Hebron Institut de Recerca
Doctor
Immunology
Cross-departmental services

Sóc metgessa immunòloga i durant la meva carrera professional em vaig especialitzar en el diagnòstic i tractament de patologies immunomediades, entre les quals es troben les immunodeficiències primàries i secundàries. També realitzo treball de laboratori contribuint al diagnòstic de les diferents patologies relacionades amb el sistema del complement.

Sóc facultativa especialista del Servei d'Immunologia de l'Hospital Universitari Vall d'Hebron. Vaig realitzar els meus estudis de medicina a la Universitat Nacional de Còrdova, Argentina i la meva especialitat, a l'Hospital Clínic Sant Carlos de Madrid, vaig enfocar la meva carrera professional cap al camp de la Immunologia clínica. Vaig estendre el meu període de formació per desenvolupar un projecte en Malaltia Celíaca pel qual vaig obtenir el grau de Doctor en Medicina per la Universitat Complutense de Madrid (excel·lent Cum Laude). Des de desembre de 2015 sóc facultativa especialista en el Servei d'Immunologia, responsable de l'àrea d’immunoproteïnes i juntament amb el Dr. Pujol-Borrell portem la consulta d'Immunologia clínica d'adults. Sóc membre de societats científiques, entre les quals destaquen la Societat Espanyola d'Immunologia (SEI), Societat Europea d'Immunodeficiències (ESID) i, la Societat Catalana d'Immunologia (SCI).

Research lines

Genetics and immunological factors in COViD-19

Determinants of severity in COVID-19 are still poorly understood but are suspected to be predominantly host factors. Besides age, sex and previous comorbidities, we investigate two other general host factors:


1-Genetic variants causing life-threatening COVID-19: We are mostly focused in genetics of immune system. This research line is under the COVIDHGE consortium.


2-The state of the immune system seems to be an important factor but the immunotypes of risk have not yet been clearly defined. The aim of this line of research is to identify the immune mechanisms that determine the severity of SARS-CoV-2 infection in order to propose and validate biomarkers of prognosis and therapeutic requirements.

IP: Manuel Hernández González, Roger Colobran Oriol, Romina Dieli Crimi, Mónica Martínez Gallo

Projects

COVID-19, PERFIL INMUNOLÓGICO DE RIESGO

IP: -
Collaborators: Manuel Hernández González, Mónica Martínez Gallo, Moisés Labrador Horrillo, Gema Codina Grau, Albert Blanco Grau, Andres Antón Pagarolas, Antonio Álvarez Fernandez, Nuria Fernández Hidalgo, Roser Ferrer Costa, Esteve Ribera Pascuet, Juan Carlos Ruiz Rodriguez, Jaume Ferrer Sancho, Anna Suy Franch, Pere Soler Palacín, Albert Selva O'Callaghan, Tomàs Pumarola Suñé, Isabel Ruiz Camps, Daniel Alvarez De la Sierra, Andrea Martín Nalda, Eva Polverino, Romina Dieli Crimi, Romina Dieli Crimi
Funding agency: Instituto de Salud Carlos III
Funding: 229000
Reference: COV20/00416
Duration: 08/05/2020 - 08/11/2021

Modelo predictivo del riesgo de infección y rechazo después del trasplante renal basado en la combinadición de parámetros clínicos y biomarcadores.

IP: Francesc Moreso Mateos
Collaborators: Joana Sellarés Roig, Concepció Jacobs Cachá, Maria de Oreto Prat Canet, Manel Perelló Carrascosa, Romina Dieli Crimi, Nestor Gabriel Toapanta Gaibor, Romina Dieli Crimi
Funding agency: Instituto de Salud Carlos III
Funding: 87120
Reference: PI18/01832
Duration: 01/01/2019 - 31/12/2022

Related news

A study from the Vall d’Hebron Campus demonstrates that the Ex Vivo C5b-9 deposition test is useful for monitoring the activity of the complement system (CS) in patients with aHUS or transplant-associated TMA.

The results show that, in some patients with mutations in the X chromosome, the healthy gene is inactivated and the mutated gene manifests itself, which favors the onset of the disease.

Researchers have used an innovative protocol to identify people with this autoimmune disease who have a higher risk of cancer.

Related professionals

Cristina Font Miñarro

Cristina Font Miñarro

Research technician
Nephrology and kidney transplantation
Read more
Raquel Villegas Pastor

Raquel Villegas Pastor

Tècnic/a Superior Recerca
Experimental Surgery Unit (ESU)
Preclinical Core Facilities
External Strategy Directorate
Read more
María José Ayala Rodas

María José Ayala Rodas

Research technician
Infectious Diseases
Read more
Núria Fernández Moreno

Núria Fernández Moreno

Research assistant
Multidisciplinary Nursing Research Group
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.